contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nightingale-health-possible-breakthrough-moves-further-away

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Head of Nordic ER Development, Analyst

Antti Luiro

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Press Release Significant Study: Nightingale Health’s Blood Analysis Helps Prevent 44% More Heart Attacks and Strokes Compared to Current Healthcare Practice December 17, 2025 Nightingale Health Nightingale Health Plc | Press Release | December 17, 2025 at 09:30:00 EET An independent study shows that Nightingale Health’s blood analysis can improve the prevention of heart attacks and strokes by 44% when used in population-level health screenings. The test identifies high-risk individuals not detected by current tools used for identifying disease risks. The study was conducted by world-leading cardiovascular researchers from the University of Cambridge and published in the prestigious main journal of the European Society of Cardiology (European Heart Journal). The study result is based on data from approximately 300,000 middle-aged Britons, which was modeled to assess the impact of adding Nightingale Health’s test to SCORE2, a cardiovascular disease risk calculator commonly used in Europe. Better prevention with Nightingale Health’s test is possible because the blood values analyzed by Nightingale Health more accurately identify individuals who should be recommended cholesterol-lowering treatment. The study states that this improvement would not increase the number of individuals treated per prevented heart attack. “One of the key findings of our study is that adding metabolomics to current cardiovascular health screening could bring significant population-level health benefits if applied widely,” says Professor Michael Inouye, principal investigator of the study from the Cardiovascular Epidemiology Unit at Cambridge. Nightingale Health’s blood analysis is a clinical tool that is scalable for the entire population and has been approved for healthcare use in the European Union, the United Kingdom, Japan, and Singapore. In Finland, the blood analysis is used in national healthcare, and over 200,000 people have already received their test results. In addition to cardiovascular disease risk, Nightingale Health’s technology simultaneously identifies the risk of type 2 diabetes, chronic kidney disease, and fatty liver with a single test, and with comparable or better performance than current healthcare tools used for identifying disease risks. “This study provides extensive evidence that Nightingale Health’s blood analysis can fundamentally improve the prevention of cardiovascular diseases. A 44% improvement in preventing heart attacks and strokes is a significant leap towards a healthier population. Importantly, this groundbreaking result can be achieved by using conventional cholesterol-lowering treatment, prescribing it to those who need it most. The study shows that Nightingale Health’s blood analysis is superior in finding precisely these individuals in a scalable way,” says Teemu Suna, CEO and Founder of Nightingale Health. “For healthcare systems, this means the opportunity to prevent more heart attacks and strokes without increasing the number of treated individuals per prevented heart attack. For doctors, it means having a scalable, evidence-based tool available that reveals hidden risk in patients who appear healthy based on current risk identification methods. For patients, it means a more effective and simpler way to avoid heart attacks and strokes. We are proud to help healthcare systems in Europe and around the world take a big step towards more efficient, proactive, and cost-effective healthcare,” Teemu Suna continues.

A press release is coming out. This study also sounds promising. This stock certainly has potential if it starts to show as cash flow at some point.                   Inderes              Merkittävä tutkimus: Nightingale Healthin verianalyysi auttaa estämään 44 %...    Nightingale Health Oyj | Lehdistötiedote | 17.12.2025 klo 09:30:00 EETRiippumaton tutkimus osoittaa, että Nightingale Healthin verianalyysi voi parantaa sydäninfarktien ja aivohalvausten ehk...

Here are Antti & Antti’s comments on Nightingale’s management team changes.  Nightingale Health announced on Friday that it is reforming its management team composition. With the changes, the scientific director will step down, and the company will recruit a medical director. This news is a continuation of the CFO change announced earlier in the week, and in light of these, Nightingale is now rebuilding its leadership to better support the growth phase of the company’s healthcare business. The background to these changes is, in our view, logical, as Nightingale has already in recent years shifted the focus of its strategy towards the commercial scaling of its technology. The news does not cause immediate pressure for changes to our forecasts.                   Inderes              Nightingalen johtoryhmän muutokset jatkuvat  - Inderes    Uutisten valossa Nightingale uudelleenrakentaa nyt johtoaan tukeakseen paremmin yhtiön terveydenhuollon liiketoiminnan kasvuvaihetta.

A couple of months ago, I pondered that the company’s board is very homegrown for a global growth phase, and indeed, so is the management team. Finally, we are starting to build what is needed for the international growth phase, but the execution is very cautious, and at least a year late. As I already wrote in the options chain, I prefer leadership that boldly builds the future a bit ahead of time, not belatedly. Well, better now than never, but at least a couple of new people also on the board, and more people who have already earned their stripes in the management team!

Damn it. I have a hunch that Barrett is leaving on his own initiative. He is the only person in the company’s management team who has managed to communicate the importance of technology in a way that others besides geeks understand, and Suna has not shown any signs of learning. As a reminder of Barrett’s communication skills, here’s the May webinar I commented on at the time:  \u003e Jeffrey Barrett’s description of the scientific basis of the analysis (starting at 17m30s) is the best description of Nightingale’s differentiation I’ve heard so far - especially better than the CEO’s high-level fluff. Similarly, Charles Alessi’s (starting at 33m) example of data usage in a clinical context is excellently practical. To my knowledge, Nightingale has not communicated things like this before. CEO Suna, on the other hand, has been rambling about the same things for at least seven years, since I first heard him. Those talks haven’t significantly built credibility. https://youtu.be/mb64f6iEMqE I wouldn’t be worried about the continuation of scientific development; they’ve been able to develop science until now. But where are product development, commercial development, and SALES development? Just over a year ago, I considered this a fairly risk-free stock in my portfolio, especially compared to my previous position, but since then, a third of the capital has melted away while the rest of the market has risen by a third. It wasn’t risk-free, and with these steps, the risks don’t seem to be decreasing.

Nightingale Health Plc | Stock Exchange Release | December 12, 2025 at 2:55:00 PM EET With the expansion of the international availability of Nightingale Health Plc’s blood analysis technology for identifying disease risks and the healthcare implementation projects, the company is renewing the composition of its management team. The main focus of the new composition is on expanding the clinical use of the company’s technology globally and accelerating its commercial growth phase. The company will continue its product development investments, but the focus will shift to the growth phase of the healthcare business. The following changes will take place in the composition of the management team to implement the reform: Jeffrey Barrett, Chief Scientific Officer (CSO), who has served on Nightingale Health Plc’s management team since September 2021, will step down from his position no later than March 2026. The company will not hire a new Chief Scientific Officer but will initiate recruitment for a Chief Medical Officer (CMO). The new person’s task will be to enhance the management team’s expertise in practical clinical work and the commercial implementation of new medical methods. The company’s current management team members, Dr. Salla Ruosaari, Chief Product Development Officer, and Antti Kangas, Chief Technology Officer, one of the company’s founders, will temporarily take responsibility for leading the company’s scientific work. The company announced a change in its Chief Financial Officer on December 8, 2025. The company has started recruiting a new Chief Financial Officer. The main focus of the new person’s role is to plan and implement functions that support the company’s international commercial growth phase and to support sales growth. Following these changes, Nightingale Health Plc’s management team will focus significantly more strongly on supporting the growth phase of the healthcare business. “We are moving into the next phase of realizing our vision, and to support this, we are renewing the composition of our management team. This way, we can better achieve our ambitious goals of making better healthcare accessible to everyone. I want to thank Jeffrey for our years together and wish him success in the future,” says Teemu Suna, the company’s CEO and Founder.

Very good numbers for the new product! This is a good starting point, and that’s what TT also thought when deepening the cooperation.

Nightingale Health

Nightingale’s H2 figures were weak throughout. The targets for the new fiscal year were also more conservative than our expectations and suggested that the potential for stronger growth is further...

<p>Nightingale’s H2 figures were weak throughout. The targets for the new fiscal year were also more conservative than our expectations and suggested that the potential for stronger growth is further down the road than we assumed. Therefore, we lowered our estimates considerably. In the short term, the high risks associated with the company's growth and valuation levels have realized and our views have been dramatically wrong. We still see preconditions for the company to achieve a significant commercial breakthrough with its technology in the future, but in the light of current information we do not expect any clear signs of this appearing in the next few years. We believe that the combination of slower growth and a highly cash-flow-negative development phase offers little critical short-term supporting points for valuation, especially in the current weakened capital market. </p> 

	2022	23e	24e
Revenue	2.2	2.9	4.8
growth-%	6.0 %	30.5 %	66.8 %
EBIT (adj.)	-11.1	-12.9	-11.7
EBIT-% (adj.)	-501.8 %	-447.9 %	-243.3 %
EPS (adj.)	-0.20	-0.22	-0.20
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	3.9	neg.	neg.

Nightingale Health: Possible breakthrough moves further away

Key Estimate Figures2022-09-30

Forum discussions